Drew Pantello - ADMA Biologics Vice Development
| ADMA Stock | USD 19.95 0.03 0.15% |
Executive
Drew Pantello is Vice Development of ADMA Biologics
| Address | 465 State Route 17, Ramsey, NJ, United States, 07446 |
| Phone | 201 478 5552 |
| Web | https://www.admabiologics.com |
ADMA Biologics Management Efficiency
The company has return on total asset (ROA) of 0.1989 % which means that it generated a profit of $0.1989 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3555 %, meaning that it created $0.3555 on every $100 dollars invested by stockholders. ADMA Biologics' management efficiency ratios could be used to measure how well ADMA Biologics manages its routine affairs as well as how well it operates its assets and liabilities. As of December 4, 2024, Return On Tangible Assets is expected to decline to -0.09. In addition to that, Return On Capital Employed is expected to decline to 0.07. At present, ADMA Biologics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 269.9 M, whereas Other Assets are forecasted to decline to 0.95.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Manher MD | Atara Biotherapeutics | N/A | |
| Eric MD | Pliant Therapeutics | 60 | |
| Felipe Duran | Ibio Inc | 45 | |
| Pia Eaves | Arcus Biosciences | N/A | |
| Paul MD | Sana Biotechnology | N/A | |
| Edward Rebar | Sana Biotechnology | 56 | |
| Kristi Sarno | Ibio Inc | N/A | |
| John Bluth | BioCryst Pharmaceuticals | 51 | |
| Huw Nash | Stoke Therapeutics | 57 | |
| Anhco Nguyen | Atara Biotherapeutics | 51 | |
| Thomas Englese | Tonix Pharmaceuticals Holding | 50 | |
| Kimberly Garko | Akebia Ther | N/A | |
| Carolyn Rucci | Akebia Ther | N/A | |
| Christian MBA | Sana Biotechnology | 41 | |
| Steven MD | Akebia Ther | 63 | |
| Douglas MBA | Akebia Ther | 63 | |
| Thomas Hare | Madrigal Pharmaceuticals | N/A | |
| Jinky Rosselli | BioCryst Pharmaceuticals | N/A | |
| Ryan Fischesser | Caribou Biosciences | N/A | |
| Amy CFA | Caribou Biosciences | N/A | |
| Clayton Fletcher | BioCryst Pharmaceuticals | N/A | |
Management Performance
ADMA Biologics Leadership Team
Elected by the shareholders, the ADMA Biologics' board of directors comprises two types of representatives: ADMA Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ADMA. The board's role is to monitor ADMA Biologics' management team and ensure that shareholders' interests are well served. ADMA Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ADMA Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, CFO VP | ||
| Michael Goldstein, Sr Counsel | ||
| Neal Fitzpatrick, Vice Sales | ||
| Kaitlin Kestenberg, Project Compliance | ||
| Cyndi Tolman, VP Services | ||
| Brian CPA, CFO VP | ||
| Dr DPS, CoFounder Chairman | ||
| Skyler Bloom, Senior Strategy | ||
| Brad Tade, CFO Treasurer | ||
| Cindy Petersen, Executive Resources | ||
| Adam Grossman, President CEO, Director | ||
| Drew Pantello, Vice Development | ||
| PharmD BCOP, Ex Engagement | ||
| John Hafl, Executive Sales | ||
| Michael Least, VP Operations |
ADMA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ADMA Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.36 | ||||
| Return On Asset | 0.2 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.33 % | ||||
| Current Valuation | 4.68 B | ||||
| Shares Outstanding | 236.39 M | ||||
| Shares Owned By Insiders | 2.51 % | ||||
| Shares Owned By Institutions | 90.88 % | ||||
| Number Of Shares Shorted | 14.24 M | ||||
| Price To Earning | (1.55) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ADMA Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ADMA Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Adma Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Adma Biologics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 14 | Earnings Share 0.27 | Revenue Per Share 1.661 | Quarterly Revenue Growth 0.781 | Return On Assets 0.1989 |
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ADMA Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.